IJBPAS, August, 2022, 11(8): 3769-3776

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

CONTRACT RESEARCH ORGANISATIONS IN INDIA- A REVIEW

R. VINOTH[1*], P. PANDIAN[2], K. KATHIRESAN[3]

1: PG Student, Department of Pharmacy, Annamalai University, Chidambaram, Tamil Nadu, India

2, 3: Associate Professor, Department of Pharmacy, Annamalai University, Chidambaram, Tamil Nadu, India

***Corresponding Author: R. Vinoth: E Mail:** vinothbpharm16@gmail.com

Received 16th Sept. 2021; Revised 20th Oct. 2021; Accepted 12nd Dec. 2021; Available online 1st Aug. 2022

https://doi.org/10.31032/IJBPAS/2021/11.8.6314

ABSTRACT

The Contract Research Organization (CRO) is a recruited entity who has the appropriate expertise and skills to undertake and accomplish the responsibilities of a sponsor. CROs offer various solutions which reside inside the Good Laboratory Practice (GLP), Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) domains beyond the limits of those areas. The global market value of CRO is anticipated to exceed $ 45 billion in 2022. It provides an alternative for the pharmaceutical company to do all of its work. The need for a CRO is an indispensable part of Pharma society.

Keywords: Contract research organization, Good manufacturing practice, Global CRO market

INTRODUCTION

A Contract Research Organization (CRO) is a service organization that offers an alternative to the pharmaceutical industry. CROs give their customers wide pharmaceutical research services to aid in the research and innovation process for pharmaceuticals and medical devices. It supports pharmaceutical and biotechnology companies for drug development and medical devices by providing outsourcing services **[1]**. Meeting the growing demand for biopharmaceuticals, increasing government support for the manufacture of biopharmaceuticals, and booming in clinical trials are the key factors driving the stable increase of the overall market for contract research organizations. Formulation and production, medical and

safety monitoring, clinical trial management, toxicology, preclinical, product development, and clinical laboratory services to process assay specimen monitoring, biostatistics, and healthcare writing assistance for the development of USFDA (NDA) New Drug Applications, regulatory assistance, (ANDA) Abbreviated New Drug Applications and several other ancillary services are among the many services provided by CROs. CROs are divided into two categories: preclinical and clinical. Therapeutic screening/design phase, chemical synthesis/device production, toxicity/biocompatibility, and functional effectiveness/repair are the four categories of preclinical research **[2]**. As a result, CRO's continues to positive development and has become associated with medical sciences, from its idea to commercialization. Because the sector is typically recession-proof and has considerable exclusive growth, the CRO is a secure investment opportunity.

HISTORY

In the early 1980s, a pharmaceutical company was expected to do all of its work. Sometimes they faced capacity problems. So, the need for excess capacity has increased, which led to the formation of the first CRO. The early CROs filled the gap by providing additional capacity when internal resources became limited. The boom in the biotech industry was led to a sharp increase in demand for CRO services, as many smaller firms are had plenty of money but deficient in internal capacity, they sought to improve their developmental projects. They need help from CROs for their work. As firms strive to broaden their product portfolio and overseas subsidiaries, the fragmented structure of the CROs sector has caused a spike in joint ventures, acquisitions, strategic partnerships, and other collaborations. CROs are now full-service collaborators, not just service suppliers **[3]**. In India, it is estimated to reach USD 45 billion by 2022. As a result of the increased outsourcing from Western nations, Indian entrepreneurs and multinational pharmaceutical corporations have established CROs in India. In China, the US Food and Drug Administration (FDA) has established its regular offices and examined all CROs that submitted GLP toxicity studies in support of different IND and NDA applications.

PARTNERSHIP BETWEEN SPONSORS AND CRO'S

Strategic alliance with CROs may enhance confidence and encourage greater transparency and recurrent information about goals and project parameters, enabling groups to tackle challenges from a variety of centers for operations and corporate cultures, Flexible Alliances and Agreements The collaboration models

presented below emphasize the complexity and diversity of interactions between pharmaceutical corporations and CROs **[4]**.

a) Privileged partnerships
b) Upstream integration
c) Subcontracting model
d) Outsourcing Large pharmaceutical and biotech businesses, occasionally a university, collaborate with a CRO
e) Small partnerships, small biotech enterprises (possibly with scientific personnel) outsource entire product discovery to CROs.

CRO'S IN CLINICAL RESEARCH

These organizations may aid during the viewing of many molecules over a span of 10 to 12 years, spending millions of money, prior bring into fruition of effective product introduction into the trade. CROs have undertaken three major kinds of trials,

1. Phase 1, delivers the research work on bioequivalence and biosimilars, which seems executed by Indian enterprises and also by overseas sponsors interested in the development of generic medications.
2. Phase 3b studies, it is the tiny mandatory trials by Indian authorities before medicine has access to Indian markets; this is a unique necessity for overseas pharmaceuticals for advertising their goods in India.
3. Multi-site randomized controlled trials situated in India, funded by foreign pharmaceutical corporations **[5]**. The latter paradigm was especially prominent among Indian CRO-biotechnology businesses.

REQUIREMENTS OF CRO:

It must have technical capabilities, quality, lead times and pricing. In the era of biosimilars and goods, the overall performance is substantially reduced when working with the desired commercial product which reduces the avoidable failures. It must have strong quality assurance activities to guarantee that all the outputs should fulfil worldwide regulatory compliance. Inspectors and accountants are continually inspecting the CROs so that it becomes one of the most probably inspected companies in India **[6, 7]**. Clear sailing through the quality audit done inside the organization is essential for survival in the vast ocean. Generally, an Indian CRO is rated based on characteristics such as creativity, ICH compliance, economic security, profitability, and reasonable price, overall quality, skill sets, global influence, character and public perception, verification, working environment, and attrition. To put studies in a CRO, you first need to find a CRO to work with. There are plenty of adverts and listings in

publications, books and journals which may be quite beneficial **[8-10]**. CROs frequently attend scientific gatherings, which gives a large quantity of knowledge via visits and personal contacts at these activities.

CRO'S GROWTH AND INVESTMENT

The worldwide CRO market is expected worth $ 35.09 billion in 2018 and is anticipated to reach $ 45 billion by 2022. The Clinical Contract Research Survey suggested that from the beginning, several firms reassess the research, development and assembling of their workouts to lower the expenses. The government organizations have handed their clinical studies to CROs and then they may run clinical studies with needed infrastructure and to decrease costs and time. Sometimes the budgets might slow down, noting that the many pharma businesses had intended to invest more than $ 50 million / year on contract research services, but it has gradually reduced from 56 per cent in 2016 to 47 per cent in 2017. The Low investment by the corporations has led to the decline of the latest pharmaceuticals authorized by the FDA from 41 in 2014, 45 in 2015 and 19 in 2016. CROs facilitate the approval procedure and lowering of the cost of releasing new pharmaceuticals to market **[11]**.

SMALLER FIRMS

Small molecules like most of the firms in India which are chemical companies, but many biologics are becoming biopharmaceutical enterprises. The government of India, together with the large Indian drug manufacturers, accepted that they can bring the modifications in current trade oriented research activities by advancing their basic research and attracting an international clinical trial to create an international based pharmaceutical industry based on innovation, so that local drug manufactures may evolve from generic trade to innovative work. When the CROs had moved into the Indian pharma market, two separate movements are made plain. One is Indian biotech and Pharma companies are attempting to flourish in innovative research and development, by exploring the accessibility to worldwide markets by accessing funding from huge corporations and the other one is global collaborators wishing to venture into India requires local skills for manufacturing.

RAPID GROWTH

The worldwide pharmaceutical industry was projected at USD 115.7 billion in 2016, 49 per cent of which is ascribed to contract research organizations (CROs). In India, the contract research market is predicted to increase from roughly $ 1 billion in 2016 to $ 1.97 billion by 2023, according to a Market Research Future study **[12]**.

Intended Audience

a) Government Research Laboratories
b) Private Research Centers
c) Research and Development (R&D) Industries
d) Medical Devices Suppliers
e) Market Research and Consultant Vendors

MARKET DEMANDS

Currently, India controls a minor fraction of the world markets in clinical studies firms, however, it is projected that it will undertake approximately 5 per cent of international clinical studies by 2012. The world CRO industry was valued at 18 billion dollars in 2008 and the segment is predicted to increase at an annualized rate of 14 per cent between 2009 and 13. Many international pharmaceutical corporations are moving into the Indian industry, working with Indian Pharmaceutical Manufacturers.

The global contract research organizations market study provides the historical market data in terms of values in 2018 and 2019, assessed current information in 2020 and forecasts for 2027 - by services (preclinical studies [pharmacokinetics], clinical research [phase II and phase III], laboratory services, therapeutic area (oncology and immunology), and geography) **[13]**. The study also assesses the industrial competitors and evaluates their market shares at a global and regional level.

Indian CRO market in 2020 requires industry size, share and revenue analysis till 2023

As clinical investigations, product development such as pharmaceutical research or process design such as bioanalytical quality testing on a contractual basis. The Indian CRO market has been valued to achieve a significant market valuation of USD 986.9 million, with a CAGR of 12%, over the forecast period of 2017 to 2023 **[14,15]**. **Figure 1** shows the shares of the Indian CRO at the end of 2020.



Figure 1: Indian CRO Market Share by End Users 2020

CHALLENGES FOR CRO'S IN INDIA

The Challenges for CRO's are mainly based on the following major areas [16-18].

a) Financial challenges.
b) Regulatory challenges.
c) Shortage of ICH-GCP Certified Search Sites.
d) Emergence in non-accredited CROs.
e) Lack of patient awareness.
f) Merchandising at contract prices.

Some more situations where difficulties might develop are, [19]

a) Changes in important persons in the project or organization.
b) Lack of clarity in the boundaries of power and obligations of signatories.
c) Lack of respect and slippage in meeting scheduled milestones; failure of regulatory validation.
d) Limitations in quality checks methods or quality management systems.
e) Inadequate or incorrect choice of suitable software to gather information.
f) An appropriate shutdown of the assessment site.
g) Poor information, miscommunication or distorting of the reality.
h) The employment of quiet or sneaky workers.
i) Occurrence of a probable dispute of agreements.

DRAWBACKS INDIAN CRO'S

CROs are appearing around the world. The formation and growth of the modern CROs are the product of superior technology and capabilities in the many nations hosting those modern CROs. But, Some of the Indian CROs lack trained and lack experience in CRO Services **[20, 21]**. Some of the Indian laboratories prefer to produce too clean toxicology results for local verification and registration purpose, omitting ill, expired, and out of bounds animals, resulting in the exaggeration of security and underestimate of toxic effects which leads to evaluate the Indian CROs at the poorest.

CONCLUSION

The significant increase of testing activities in India needed the active cooperation of local enterprises and researchers. Inside the research-based pharmaceutical organizations, Indian CROs have served both globally and locally, new concerns have emerged in the moral discussion with surrounding pharmaceuticals. While admittance to drugs is important for drug improvement, CROs gives excitement for business researchers to care about the wider patient health concerns after clinical studies conclude for our society, the key focus of corporate scientists was the safety and security of

research participants those who involved in the study. Indian biotech and pharma enterprises are doing both generic work and investigation on novel substances (particularly phase 1 trial), bioequivalence and biosimilar studies with the support of CROs, the multinational pharmaceutical firms that contract with the local CROs to research in India. So, that the need for a CRO is an indispensable part of Pharma society.

REFERENCES

[1] Mei-Shu Shih, Roles of contract research organizations in translational medicine, Journal of Orthopedic Translation, 3(2), 2015, 85-88.

[2] Sushma Drabu, Alka Gupta, Anupama Bhadauria, Review of Emerging trends in contract research industry in India, Contemporary clinical trials, 31, 2010, 419-422.

[3] Contract research on the rise, www.TheScientist.com, [accessed on september 2021].

[4] John L. LaMattina, The impact on mergers of pharmaceutical R & D, Nature reviews drug discovery, 10, 2011, 559-560.

[5] Salla Sariola, Deapica Ravindran, Anand Kumar, Roger Jeffery, Big-pharmaceuticalisation: Clinical trials and Contract Research Organisations in India, Social science and Medicine, 131, 2015, 239-246.

[6] Shayne C. Gad Charles, B. Spainhour, David G. Serota, Contract Research and Development Organizations- Their History, Selection, and Utilization, 1, Elsevier Inc, PA USA, 2014, 418.

[7] Contract research organization, http://www.absoluteastronomy.com, [accessed on september 2021].

[8] The Role of Pharmacovigilance in Clinical Trials, https://sollers.edu/, [accessed on October 2021].

[9] http://en.wikipedia.org/wiki/Drug_development, [accessed on October 2021].

[10] Richards RG, AO Research Institute Davos within the AO Foundation: a model for translation of science to the clinics. Journal of orthopaedic Translation, 1, 2013, 11-18.

[11] Global-healthcare-cro-market, http://www.grandviewresearch.com/, [accessed on October 2021].

[12] Pharmaboardroom.com/articles/indian-contract-research-industry-set-for-rapid-growth, [accessed on October 2021].

[13] Datta PT, Jyothi, Clinical trial to fall short of billion-dollar projection, [accessed on October 2021].

[14] Reports from Meticulous Market Research Pvt. Ltd, https://www.meticulousresearch.com/product/CRO-market-5129, [accessed on October 2021].

[15] India CRO market, https://www.marketresearchfuture.com/reports/india-cro-market-2927 [accessed on November 2021].

[16] Biswas P, Biswas AK, Setting standards for proactive pharmacovigilance in India: The way forward, Indian journal of pharmacology, 39, 2007, 124-128.

[17] Sawant P, Roychowdhury, what are the three main challenges faced by the Indian clinical market? www.pharmabioworld.com, [accessed on November 2021].

[18] Samiran Nundy, M. Chir, Chandra M. Gulhati, A new colonialism conducting clinical trials in India. The New England Journal of Medicine, 352(16), 2005, 1633-1636.

[19] Working with study directors, Contract Pharma.com, [accessed on November 2021].

[20] Murti Y, Verma P, Pathak D, Awareness of the risk factors in volunteers of clinical trials. The Pharma Review, 6, 2009. 68-74.

[21] Chaganti Dhanunjaya Reddy, N. Vishal Gupta, Overview on Contract Research and Manufacturing Services (Crams) And Its Present Status in India, Asian Journal of Pharmaceutical and Clinical Research, 6 (2), 2013, 33-37.